Full reference for the Thymosin Beta-4 synthetic fragment — mechanism, evidence, dosing protocol, safety, and current COA-verified vendor pricing.
Research context only. This page is for educational purposes based on published data. Not medical advice.
TB-500 is a synthetic analog of the active region of Thymosin Beta-4 — a 43 amino acid protein naturally present in blood platelets and wound fluid. It is one of the first responders in the body's healing cascade, upregulated significantly at injury sites. The synthetic fragment (amino acids 17-23) retains the core bioactivity of the full protein while being more practical to synthesize and administer.
TB-500's primary mechanism is the sequestration of G-actin (monomeric actin), which lowers the intracellular concentration of free G-actin. This shifts the equilibrium of actin polymerization in ways that facilitate cell motility — cells become better at migrating toward damaged tissue.
Simultaneously, TB-500 upregulates VEGF (vascular endothelial growth factor), driving angiogenesis at repair sites. New blood vessel formation is critical for tissue regeneration — it delivers oxygen, nutrients, and additional repair cells to the healing zone. TB-500 also downregulates pro-inflammatory cytokines including NF-κB, reducing the inflammatory burden that impedes chronic healing.
The cardiac angle: TB-500's ability to recruit stem cells and reduce ischemic damage has made it a subject of serious cardiac repair research. Studies in rodent MI models showed meaningful cardiomyocyte survival improvements. This is an active area of legitimate pharmaceutical research, not just athletic optimization.
| Research Area | Evidence Level | Key Findings |
|---|---|---|
| Tendon healing | Strong (animal) | Accelerated tendon repair, collagen organization, reduced scar formation |
| Muscle repair | Strong (animal) | Faster satellite cell recruitment and myofiber regeneration |
| Cardiac repair | Moderate (animal) | Stem cell migration, cardiomyocyte survival, reduced infarct size |
| Wound healing | Strong (animal + equine) | Accelerated skin and corneal wound closure |
| Anti-inflammatory | Strong (animal) | NF-κB and TNF-α suppression confirmed |
| Human clinical | Limited | Primarily veterinary; human data largely observational |
| Parameter | Value | Notes |
|---|---|---|
| Loading dose | 2–2.5mg | Twice weekly for 4 weeks |
| Maintenance dose | 2mg | Once weekly after loading |
| Total cycle | 8–12 weeks | 4 loading + 4–8 maintenance typical |
| Administration | SubQ or IM | Site-independent due to systemic action |
| Reconstitution | 1–2 mL BAC water | Standard; refrigerate after mixing, use within 4 weeks |
COA-verified vendor pricing with promo codes, reconstitution guide, and dosing protocol.
View Pricing → Dosage Calculator